- In April 2023, Stallergenes Greer, a global biopharmaceutical company specializing in allergen immunotherapy, announced the expansion of its sublingual immunotherapy (SLIT) tablet portfolio with the launch of a new birch pollen tablet in select European markets. This development aims to address the growing prevalence of tree pollen allergies and reinforces the company’s commitment to offering patient-friendly, evidence-based treatments tailored to regional allergen sensitivities. The new launch strengthens Stallergenes Greer's leadership in personalized allergy immunotherapy
- In March 2023, HAL Allergy Group, a leading European developer of allergen products, initiated a Phase III clinical trial to evaluate the efficacy and safety of its house dust mite subcutaneous immunotherapy (SCIT) candidate in pediatric populations. This trial marks a key step in expanding treatment options for children suffering from chronic respiratory allergies and reflects HAL's strategic focus on delivering long-term, disease-modifying therapies to underserved age groups
- In February 2023, ALK-Abelló A/S, a global leader in allergy immunotherapy, received regulatory approval in Japan for its SLIT tablet targeting Japanese cedar pollen allergy. This milestone aligns with ALK’s expansion strategy in Asia and responds to the country’s high prevalence of cedar pollen allergies. The product’s approval provides Japanese patients with a convenient, at-home treatment alternative during peak allergy seasons, underlining ALK’s focus on global accessibility and tailored solutions
- In January 2023, Anergis SA, a clinical-stage biopharmaceutical company based in Switzerland, announced a strategic R&D collaboration with Virometix AG to advance ultra-fast allergy immunotherapy candidates. The partnership focuses on leveraging virus-such as particle (VLP) technology to deliver short-course allergy vaccines with long-term efficacy. This initiative showcases a growing trend toward innovative platforms that reduce treatment duration while maintaining strong immune tolerance
- In January 2023, Allergy Therapeutics plc, a U.K.-based specialty pharmaceutical company, commenced a Phase I trial for its virus-such as particle-based peanut allergy vaccine candidate. This first-in-human trial represents a significant advancement in food allergy immunotherapy and signals the company’s efforts to diversify beyond respiratory allergies. The program highlights an industry-wide push toward addressing complex and life-threatening allergies with next-generation vaccine technologies
